IGF-1 LR3: research reference

Preserve the particular preparation and assay. Declared mass does not substitute for measured activity, and a protein name does not resolve all its forms.

The IGF-1 receptor is a receptor tyrosine kinase that activates PI3K-Akt and MAPK pathways in cellular models. The substitution at position 3 reduces sequestration by IGFBPs in in vitro studies.

The purity value is a product-label specification, not an assay result. A batch result can only be asserted from that batch’s certificate.

These names help identify the catalog entry. A descriptive label is not evidence of efficacy, and structural identity still requires appropriate documentation.

Growth factor

Reconstitution: Laboratory procedure: allow the closed vial to reach room temperature, disinfect the septum and slowly transfer the diluent against the inner wall of the vial. Do not shake; gently swirl the vial until fully dissolved. Record the volume, diluent and date in the batch log.

Storage: Sealed vial of lyophilized material: store at −20 °C, protected from light and moisture. Avoid repeated freeze-thaw cycles of reconstituted material; aliquot when the experimental design permits.

Personal protective equipment: Handle in a clean work area with a lab coat, nitrile gloves and eye protection. Dispose of vials, tips and sharps according to the laboratory waste procedure.

The bibliography covers four biological settings with different measurements. Initial in vitro studies used L6 myoblasts, H35 hepatoma cells and fibroblasts to compare precursor incorporation into protein and DNA with protein degradation. Relative potency among related variants changed depending on whether the cell line secreted binding proteins into the medium (1378742, 1311930).

Animal work compared low-binding-protein-affinity analogs with the native factor in pigs of different ages and growth-hormone responsiveness, measuring growth and metabolic endpoints (8817682). Rodent experiments separated molecule identity from delivery timing by comparing sustained and pulse exposure in normal and catabolic rats (8708565). A 2025 preclinical study in late-gestation growth-restricted sheep fetuses measured fetal weight and insulin response to a glucose challenge, reporting a negative growth endpoint (39679943). A further analytical paper characterized material recovered from the illicit market using immunoaffinity and mass spectrometry (20675162). Sources: PMID 1378742; PMID 1311930; PMID 8817682; PMID 8708565; PMID 39679943; PMID 20675162.

None of these references publishes a half-life, elimination constant, degradation route or albumin-binding finding. Albumin binding concerns other catalog molecules. What is described is the control of availability.

In vitro, the potency advantage of the Arg3 variant appears in cell lines secreting binding proteins and disappears in those that do not, locating the difference in IGFBP sequestration rather than type 1 receptor affinity (1378742, 1311930). In animals, the difference between analog and native factor persists with sustained and pulse input, supporting a molecular rather than delivery-pattern explanation (8708565). Pig studies add endocrine context: age and growth-hormone responsiveness condition the observed response (8817682). The published profile is qualitative—what governs availability, not how long it lasts. Sources: PMID 1378742; PMID 1311930; PMID 8708565; PMID 8817682.

The molecule originated as a laboratory tool. A 1992 Escherichia coli expression system produced the growth factor fused to an amino-terminal extension from porcine growth hormone, followed by inclusion-body recovery, cleavage, refolding and purification (1311930). Glycine and arginine substitutions were tested at position 3. The arginine variant retaining the fusion extension is named Long [Arg3] in the literature (1311930, 1378742).

The stated purpose was comparative: produce sufficient related variants to separate receptor binding from escape from binding proteins as contributors to in vitro potency (1378742). Because this is an expression construct, its identity depends on the specific construct. A 2010 analytical report found a histidine-tagged version in a vial from the illicit market, indicating a production system different from the foundational literature’s material (20675162). Sources: PMID 1311930; PMID 1378742; PMID 20675162.

The catalog places this reference near secretagogues and recombinant growth hormone, but they enter the axis at different points. Sermorelin and both CJC-1295 variants are short synthetic chains related to the releasing hormone’s amino-terminal fragment; ipamorelin is a pentapeptide with nonnatural residues. They have been studied at pituitary G protein-coupled receptors. HGH is a recombinant protein associated with a cytokine-superfamily receptor in experimental models.

IGF-1 LR3 is also recombinant, but its described target is a peripheral receptor tyrosine kinase, placing it downstream. This affects comparability rather than rank: secretagogue work measures pituitary secretion, whereas LR3 work measures whole-animal growth and metabolic outcomes (8817682, 39679943) or relative in vitro potency (1378742). Findings do not transfer between these families. Sources: PMID 8817682; PMID 39679943; PMID 1378742.

Species and outcome direction remain unresolved. The 1990s pig and rodent studies and the 2025 sheep-fetus study do not point in the same direction; no publication here explains why late-gestation growth restriction failed to reproduce earlier animal findings (39679943, 8817682, 8708565). There are no human trials in this bibliography, only preclinical, in vitro and analytical work.

Identity also remains a separate issue. The analytical paper found a tagged version differing from what was declared. No published series establishes how often that happens or what proportion of circulating material matches the foundational sequence (20675162, 1311930). Literature therefore supports statements about the articles’ molecules, not every vial bearing the name. Sources: PMID 39679943; PMID 8817682; PMID 8708565; PMID 20675162; PMID 1311930.